# A Study to Assess the Efficacy, Safety and Tolerability of IRL201104 in Adults With Active Eosinophilic Esophagitis

> **NCT05084963** · PHASE2 · COMPLETED · sponsor: **Revolo Biotherapeutics** · enrollment: 36 (actual)

## Conditions studied

- Eosinophilic Esophagitis

## Interventions

- **DRUG:** IRL201104
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05084963
- **Lead sponsor:** Revolo Biotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-29
- **Primary completion:** 2022-10-24
- **Final completion:** 2022-10-24
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05084963

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05084963, "A Study to Assess the Efficacy, Safety and Tolerability of IRL201104 in Adults With Active Eosinophilic Esophagitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05084963. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*